Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 332

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 332
---
 817,631.6 |     |                | 842,894.1 |
| Viatris Inc. (NasdaqGS:VTRS)                       |     |             |  11.57 |     |           |   8.74 |     |           |  13.62 |     |                |  13,809.0 |     |                |  30,161.4 |
| Teva Pharmaceutical Industries Limited (NYSE:TEVA) |     |             |  17.13 |     |           |   8.06 |     |           |  18.03 |     |                |  19,408.2 |     |                |  36,276.2 |
| Dr. Reddy’s Laboratories Limited (BSE:500124)      |     |             |  81.03 |     |           |  62.09 |     |           |  83.83 |     |                |  13,498.2 |     |                |  12,736.3 |
| Collegium Pharmaceutical, Inc. (NasdaqGS:COLL)     |     |             |  36.71 |     |           |  20.95 |     |           |  40.95 |     |                |   1,182.6 |     |                |   1,470.4 |
| AbbVie Inc. (NYSE:ABBV)                            |     |             | 191.23 |     |           | 135.85 |     |           | 193.91 |     |                | 337,777.9 |     |                | 395,601.9 |
| Axsome Therapeutics, Inc. (NasdaqGM:AXSM)          |     |             |  84.85 |     |           |  55.02 |     |           |   98.4 |     |                |   4,072.8 |     |                |   3,949.0 |

Notes:

| (1) | Values in millions of US Dollars. |

| (2) | Corresponding data and multiples continued in table below. |

| (3) | Source: S&P Capital IQ. |

186

Comparable Company Analysis (Continued)

| Company Name                                       |     | Sales          
 (TTM)($)(1)(2) |           |     |